Skip to main content

Niedrigere 5-Jahres-Rate an Klappendegenerationen mit der CoreValve-TAVI-Klappe im Vergleich zu chirurgischen Klappen

Low 5-year rates of valve degeneration with the CoreValve TAVI valve in comparison to surgical valves

This is a preview of subscription content, access via your institution.

Literatur

  1. Reardon MJ et al (2022) Corevalve US pivotal and SURTAVI trials show rate of SVD lower with TAVR than with SAVR. American College of Cardiology (acc.org)

  2. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, Malenka DJ, Thourani VH, Rymer J, Kosinski AS (2018) Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT registry. J Am Coll Cardiol 72(22):2701–2711

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Nikos Werner.

Ethics declarations

Interessenkonflikt

Nikos Werner ist Proktor für Medtronic und hat Forschungsförderung und Vortragshonorere von Medtronic und Edwards Lifesciences erhalten.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Werner, N. Niedrigere 5-Jahres-Rate an Klappendegenerationen mit der CoreValve-TAVI-Klappe im Vergleich zu chirurgischen Klappen. Kardiologie 16, 204–206 (2022). https://doi.org/10.1007/s12181-022-00554-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-022-00554-4